Panelists discuss how the NATALEE study at ESMO 2024 presented updates on primary, secondary, and exploratory endpoints for evaluating a new cancer treatment.
David Sallman, MD, discusses some of the innovative therapies and strategies being investigated in myelodysplastic syndromes studies.
Arnab Basu, MD, MPH, FACP, discussed his research on high-sensitivity circulating tumor DNA assays in genitourinary ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric ...
With immunotherapy-based regimens and novel agents like bispecific antibodies and antibody-drug conjugates, oncologist David ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...
Osimertinib is now an FDA-approved therapy for stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations that ...
Arnab Basu, MD, MPH, FACP, discusses his research on high sensitivity circulating tumor DNA assays in genitourinary malignancies.
Missak Haigentz, MD, discussed the implications and next steps of the ADRIATIC study in patients with limited-stage small ...
In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...
GLP-1 agonists, widely used for obesity and diabetes management, have been associated with a reduced risk of most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback